ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
1.290
-0.030 (-2.27%)
At close: Feb 4, 2025, 4:00 PM
1.280
-0.010 (-0.78%)
After-hours: Feb 4, 2025, 7:34 PM EST
ALX Oncology Holdings Stock Forecast
ALXO's stock price has decreased by -91.22% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for ALX Oncology Holdings stock have an average target of 6.64, with a low estimate of 2.00 and a high estimate of 21. The average target predicts an increase of 414.73% from the current stock price of 1.29.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ALX Oncology Holdings stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $4 → $2.2 | Strong Buy | Maintains | $4 → $2.2 | +70.54% | Jan 27, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jan 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $25 → $5 | Strong Buy | Maintains | $25 → $5 | +287.60% | Jan 24, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $12 → $2 | Strong Buy → Hold | Downgrades | $12 → $2 | +55.04% | Dec 19, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Dec 18, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.81
from -3.74
EPS Next Year
-2.55
from -2.81
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 14.5M | |||
| Avg | n/a | n/a | 3.5M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -2.75 | -2.32 | -1.89 |
| Avg | -2.81 | -2.55 | -2.40 |
| Low | -2.91 | -2.73 | -2.82 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.